Precision medicine. Personalised care.
What do we do with a piece of code 3 billion letters long? When it comes to rare diseases, we know that no two people are the same. Teams are now deploying technologies and methodologies that can treat the individual needs of each patient. In the case of neuroblastoma, when at one point two out of every three patients passed away from the disease, progress in this regard is imperative. The protocols and therapies that existed were not going to cut it. But for groups like TGen, being able to mine data from cases, coupled with a deep understanding of genomics, helps to create personalised, targeted treatment that's far superior than traditional methods, relying on Dell Technologies to help them find solutions to problems that haven't even been defined yet.